Condition: Prostate Cancer Metastatic · Sponsor: UNICANCER
PEACE-6 Poor Responders is an international, multicenter, open-label, controlled, randomized, phase III trial to evaluate the efficacy and safety of 177Lu-PSMA-617 when administered on top of the ongoing standard systemic treatment compared to standard systemic treatment alone in patients with de novo metastatic hormone-sensitive prostate cancer (mHSPC) who do not present with a satisfactory response characterized by a serum prostatic specific antigen (PSA) level of ≥ 0.2 ng/mL at 6 to 8 months after systemic treatment initiation for mHSPC (i.e. poor responders) in the absence of evidence of cancer progression (including a rising PSA level).
This description comes directly from the study's public registry record.
Florence TANTOT · +33 (1) 73.77.55.43 · f-tantot@unicancer.fr
Catherine LEGER · +33 (7) 79.83.23.98 · c-leger@unicancer.fr
Always discuss trial participation with your own doctor first.
| Institut de Cancérologie de l'Ouest | Angers, France | Not Yet Recruiting |
| Institut Bergonié | Bordeaux, France | Not Yet Recruiting |
| CHRU Brest | Brest, France | Not Yet Recruiting |
| Centre Francois Baclesse | Caen, France | Not Yet Recruiting |
| CHU Henri Mondor | Créteil, France | Not Yet Recruiting |
| Centre Georges-François Leclerc | Dijon, France | Not Yet Recruiting |
| CHU Grenoble | Grenoble, France | Not Yet Recruiting |
| Centre Léon Berard | Lyon, France | Not Yet Recruiting |
| Institut Paoli-Calmettes | Marseille, France | Recruiting |
| CHRU Nancy | Nancy, France | Not Yet Recruiting |
| Centre Antoine Lacassagne | Nice, France | Not Yet Recruiting |
| Hôpital Cochin | Paris, France | Not Yet Recruiting |
+ 13 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06496581